Anshul Maheshwari Sells 3,311 Shares of SiBone (NASDAQ:SIBN) Stock

Key Points

• Anshul Maheshwari, CFO of SiBone, sold 3,311 shares at an average price of $14.20, totaling approximately $47,016.20, reducing his ownership by 1.54%.
• SiBone's stock is currently trading at $14.49, which is below its fifty-day moving average of $15.76; the company has a market cap of $625.10 million.
• Analysts have mixed ratings on SiBone, with a consensus of "Moderate Buy" and a target price of $23.67, while recent reports have seen changes in ratings from "buy" to "hold."

SiBone (NASDAQ:SIBN - Get Free Report) CFO Anshul Maheshwari sold 3,311 shares of the company's stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $14.20, for a total value of $47,016.20. Following the completion of the transaction, the chief financial officer owned 211,134 shares of the company's stock, valued at $2,998,102.80. The trade was a 1.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Anshul Maheshwari also recently made the following trade(s):

• On Monday, August 18th, Anshul Maheshwari sold 3,461 shares of SiBone stock. The shares were sold at an average price of $15.57, for a total value of $53,887.77.

SiBone Stock Performance

Shares of NASDAQ SIBN traded down $0.01 during trading hours on Monday, reaching $14.49. The stock had a trading volume of 446,171 shares, compared to its average volume of 422,885. The business's fifty day moving average is $15.76 and its two-hundred day moving average is $16.28. The company has a debt-to-equity ratio of 0.21, a current ratio of 8.38 and a quick ratio of 7.00. The company has a market cap of $625.10 million, a price-to-earnings ratio of -25.87 and a beta of 0.83. SiBone has a twelve month low of $11.70 and a twelve month high of $20.05.

SiBone (NASDAQ:SIBN - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.05. The business had revenue of $48.63 million during the quarter, compared to analyst estimates of $48.12 million. SiBone had a negative return on equity of 14.20% and a negative net margin of 12.83%. SiBone has set its FY 2025 guidance at EPS. As a group, research analysts expect that SiBone will post -0.78 EPS for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Wall Street Zen lowered SiBone from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Cantor Fitzgerald set a $25.00 price objective on SiBone and gave the stock an "overweight" rating in a research note on Monday, August 11th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of SiBone in a research note on Saturday, September 27th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $23.67.

Hedge Funds Weigh In On SiBone

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SIBN. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in SiBone by 8.3% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 102,666 shares of the company's stock worth $1,439,000 after buying an additional 7,855 shares during the last quarter. GAMMA Investing LLC raised its position in shares of SiBone by 20,352.6% during the first quarter. GAMMA Investing LLC now owns 3,886 shares of the company's stock worth $55,000 after purchasing an additional 3,867 shares during the period. Rhumbline Advisers raised its position in shares of SiBone by 3.6% during the first quarter. Rhumbline Advisers now owns 59,721 shares of the company's stock worth $838,000 after purchasing an additional 2,100 shares during the period. Charter Oak Capital Management LLC acquired a new stake in shares of SiBone during the first quarter worth about $337,000. Finally, Elevation Point Wealth Partners LLC acquired a new stake in shares of SiBone during the first quarter worth about $204,000. Institutional investors own 98.11% of the company's stock.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.